FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310107971> ?p ?o ?g. }

• W4310107971 endingPage "6022" @default.
• W4310107971 startingPage "6020" @default.
• W4310107971 abstract "Philadelphia (Ph)-like ALL is associated with poor response to standard chemotherapy and frequently necessitates novel salvage therapies to attain remission. However, outcomes of novel therapies in relapsed/refractory (r/r) Ph-like ALL remains largely unknown, except for a few reported small case series. Here, we retrospectively studied outcomes of adult patients (pts) with r/r B-cell ALL who completed at least one cycle of a novel salvage therapy [blinatumomab (blina), inotuzumab (INO), or CD19CAR T cells (CAR)] at City of Hope from 2012 to 2022 and had post treatment disease assessment. We only included pts with documented fusions associated with Ph-like ALL, identified by accumulative results of RNAseq, conventional cytogenetics, FISH, and whole genome SNP array analysis. Complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate was the primary endpoint and leukemia-free survival (LFS) and overall survival (OS) were secondary endpoints. LFS was defined as the period from the date of response to individual therapy to the date of relapse or death, whichever came first; LFS was censored among responders. at the last follow-up if pts were alive and relapse-free. We identified 96 pts with r/r B-cell ALL with Ph-like fusions who received 149 individual novel therapies; 83 (86%) pts were treated with blina, 36 (38%) with INO, and 30 (31%) with CAR [commercial; n=10; investigational: n=20]. Median age at the time of first novel salvage therapy was 36 years (range; 18-71), 69% of pts were males and 89% were Hispanic. Ph-like fusions including IGH-CRLF2, P2RY8-CRLF2, ABL1/2,JAK2-, EPOR- and ETV6-NTRK2-fusion were seen in 50%, 27%, 8%, 9%, 4% and 1% of the cohort, respectively. Pts with CAR therapy had more prior lines of therapy compared to blina and INO (3 vs 1 vs 2; p<0.001), more frequently underwent prior allogeneic transplant (57% vs 12% vs 22%; p=0.002), and had a trend toward more extramedullary disease at the time of initiating therapy (27% vs 0 vs 6%; p= 0.065). Blina was administered at older median age compared to INO and CAR (36 vs 33 vs 29; p=0.004). Pts treated with INO had a trend toward higher marrow blasts% at the time of starting therapy (80 vs 60 vs 50; p= 0.065) compared to CAR and blina, respectively. Prior novel therapies were given for relapse to 7% (n=6), 75% (n=27), and 70% (n= 21) before blina, INO and CAR, respectively. The CR/CRi rates were 63%, 72%, and 90% after blina, INO and CAR, with corresponding negative minimal residual disease (MRD-) rate among evaluable responders (defined as <0.01% leukemic cells in the bone marrow by multicolor flow cytometry) of 86%, 73%, and 96%, respectively. Among responders, 50%, 50%, and 44% of pts receiving blina, INO or CAR, respectively; underwent consolidation with allogeneic transplant. CR/CRi rates for pts treated with INO with/without prior lines of novel therapy were 74% and 67%, respectively. CR/CRi were 90% and 89% for CAR pts treated with/without prior novel therapies. The median follow up since the first salvage novel therapy was 13.1 months (range; 0.6-109.5), and the median OS was 21.6 months (range; 15.1-27.8). In multivariable analysis, type of novel therapy (p= 0.044) and marrow blasts [per 5% increase] (p=0.006) independently predicted CR/CRi rate, while the Ph-like fusion subgroup was associated with LFS (p= 0.013), with 6-months LFS of 45%, 67%, and 90% for pts carrying IGH-CRLF2, P2RY8-CRLF2 and other fusions, respectively. Yet, LFS was not different among pts receiving individual novel salvage therapies (p=0.30), and the 6-month LFS for blina, INO and CAR were 60%, 55% and 66%, respectively. To our knowledge, our study is the largest experience evaluating outcomes of novel salvage therapies for Ph-like ALL. Our results show that novel therapies are highly effective in r/r ALL with Ph-like fusions, leading to high remission rate, MRD- response and transition to transplant consolidation at remission. Prior novel therapies did not adversely impact response to subsequent novel therapies. Therefore, the early introduction of novel therapies in pts with Ph-like ALL is of great interest and could potentially lead to improvement in frontline therapy outcomes in this high-risk entity. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310107971 created "2022-11-30" @default.
• W4310107971 creator A5004337476 @default.
• W4310107971 creator A5011812481 @default.
• W4310107971 creator A5015521146 @default.
• W4310107971 creator A5020684790 @default.
• W4310107971 creator A5024492683 @default.
• W4310107971 creator A5030822207 @default.
• W4310107971 creator A5038541414 @default.
• W4310107971 creator A5039374832 @default.
• W4310107971 creator A5040369089 @default.
• W4310107971 creator A5048360588 @default.
• W4310107971 creator A5051018931 @default.
• W4310107971 creator A5051116684 @default.
• W4310107971 creator A5052723726 @default.
• W4310107971 creator A5057523501 @default.
• W4310107971 creator A5059382599 @default.
• W4310107971 creator A5060959458 @default.
• W4310107971 creator A5061899912 @default.
• W4310107971 creator A5062815030 @default.
• W4310107971 creator A5063345064 @default.
• W4310107971 creator A5065052780 @default.
• W4310107971 creator A5066354077 @default.
• W4310107971 creator A5070193149 @default.
• W4310107971 creator A5070266139 @default.
• W4310107971 creator A5070693731 @default.
• W4310107971 creator A5072317606 @default.
• W4310107971 creator A5072747994 @default.
• W4310107971 creator A5075695505 @default.
• W4310107971 creator A5078184054 @default.
• W4310107971 creator A5081883519 @default.
• W4310107971 creator A5084027789 @default.
• W4310107971 creator A5086494836 @default.
• W4310107971 date "2022-11-15" @default.
• W4310107971 modified "2023-09-28" @default.
• W4310107971 title "Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions" @default.
• W4310107971 doi "https://doi.org/10.1182/blood-2022-158288" @default.
• W4310107971 hasPublicationYear "2022" @default.
• W4310107971 type Work @default.
• W4310107971 citedByCount "0" @default.
• W4310107971 crossrefType "journal-article" @default.
• W4310107971 hasAuthorship W4310107971A5004337476 @default.
• W4310107971 hasAuthorship W4310107971A5011812481 @default.
• W4310107971 hasAuthorship W4310107971A5015521146 @default.
• W4310107971 hasAuthorship W4310107971A5020684790 @default.
• W4310107971 hasAuthorship W4310107971A5024492683 @default.
• W4310107971 hasAuthorship W4310107971A5030822207 @default.
• W4310107971 hasAuthorship W4310107971A5038541414 @default.
• W4310107971 hasAuthorship W4310107971A5039374832 @default.
• W4310107971 hasAuthorship W4310107971A5040369089 @default.
• W4310107971 hasAuthorship W4310107971A5048360588 @default.
• W4310107971 hasAuthorship W4310107971A5051018931 @default.
• W4310107971 hasAuthorship W4310107971A5051116684 @default.
• W4310107971 hasAuthorship W4310107971A5052723726 @default.
• W4310107971 hasAuthorship W4310107971A5057523501 @default.
• W4310107971 hasAuthorship W4310107971A5059382599 @default.
• W4310107971 hasAuthorship W4310107971A5060959458 @default.
• W4310107971 hasAuthorship W4310107971A5061899912 @default.
• W4310107971 hasAuthorship W4310107971A5062815030 @default.
• W4310107971 hasAuthorship W4310107971A5063345064 @default.
• W4310107971 hasAuthorship W4310107971A5065052780 @default.
• W4310107971 hasAuthorship W4310107971A5066354077 @default.
• W4310107971 hasAuthorship W4310107971A5070193149 @default.
• W4310107971 hasAuthorship W4310107971A5070266139 @default.
• W4310107971 hasAuthorship W4310107971A5070693731 @default.
• W4310107971 hasAuthorship W4310107971A5072317606 @default.
• W4310107971 hasAuthorship W4310107971A5072747994 @default.
• W4310107971 hasAuthorship W4310107971A5075695505 @default.
• W4310107971 hasAuthorship W4310107971A5078184054 @default.
• W4310107971 hasAuthorship W4310107971A5081883519 @default.
• W4310107971 hasAuthorship W4310107971A5084027789 @default.
• W4310107971 hasAuthorship W4310107971A5086494836 @default.
• W4310107971 hasConcept C126322002 @default.
• W4310107971 hasConcept C141071460 @default.
• W4310107971 hasConcept C142424586 @default.
• W4310107971 hasConcept C143998085 @default.
• W4310107971 hasConcept C203092338 @default.
• W4310107971 hasConcept C2776694085 @default.
• W4310107971 hasConcept C2778020697 @default.
• W4310107971 hasConcept C2778461978 @default.
• W4310107971 hasConcept C2780775027 @default.
• W4310107971 hasConcept C2909962599 @default.
• W4310107971 hasConcept C535046627 @default.
• W4310107971 hasConcept C71924100 @default.
• W4310107971 hasConcept C86803240 @default.
• W4310107971 hasConcept C87355193 @default.
• W4310107971 hasConceptScore W4310107971C126322002 @default.
• W4310107971 hasConceptScore W4310107971C141071460 @default.
• W4310107971 hasConceptScore W4310107971C142424586 @default.
• W4310107971 hasConceptScore W4310107971C143998085 @default.
• W4310107971 hasConceptScore W4310107971C203092338 @default.
• W4310107971 hasConceptScore W4310107971C2776694085 @default.
• W4310107971 hasConceptScore W4310107971C2778020697 @default.
• W4310107971 hasConceptScore W4310107971C2778461978 @default.
• W4310107971 hasConceptScore W4310107971C2780775027 @default.
• W4310107971 hasConceptScore W4310107971C2909962599 @default.
• W4310107971 hasConceptScore W4310107971C535046627 @default.
• W4310107971 hasConceptScore W4310107971C71924100 @default.

• next